NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, has ...
The largest analysis of psychedelic brain imaging to date offers a clearer picture of how psychedelic drugs affect the brain.
While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external ...
Organogenesis Holdings Inc. looks undervalued at distressed multiples; new DFU RCT data supports coverage despite 2026 CMS ...
Real-world data is increasingly used to optimize trial design, reduce recruitment burden, and support regulatory decisions, but adoption remains uneven due to challenges around data quality, ...
Morning Overview on MSN
Once-controversial exon-skipping drugs return as hope for Duchenne
Exon-skipping therapies for Duchenne muscular dystrophy, a class of drugs that triggered fierce regulatory debate when they ...
Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced a $50 million growth financing.
A new wave of device code phishing shows how threat actors are scaling account compromise using AI and end‑to‑end automation.
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable ...
Major Korean K-pop agencies are accused of greenwashing when promoting digital "smart albums," while maintaining aggressive ...
Povetacicept, a dual BAFF/APRIL inhibitor, significantly lowered proteinuria in patients with immunoglobulin A nephropathy ...
The data are limited but suggest the tricuspid valve procedure can do more than improve health status, researchers say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results